Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Regulation Generic Drugs Biosimilars

Regulatory Recap: FTC And Others Support Biosimilar Interchangeability Draft Guidance

Also, Regulatory Updates From ICH, China, And FDA

  • Analysis

Executive Summary

Generics Bulletin reviews the latest regulatory events across the world.

Table

View full table

Topics

Tags:
Regulation Generic Drugs Biosimilars
Latest Headlines

Generics And Biosimilars Saved US $445bn In 2023, But Industry Stands At ‘Critical Crossroads’

Apixaban Dominates UK Rises In August

Vanda’s Hetlioz Suit Against FDA Largely Dismissed For Lack Of Ripeness

Sandoz Is ‘Not Aiming To Be A Leader’ In US Small-Molecule Generics

See All
UsernamePublicRestriction

Register

GB153731

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By